Estimates were made for 21 countries and territories in the IDF Middle East and North Africa (MENA) Region. A total of 31 data sources from 18 countries were used to estimate diabetes prevalence in 20-79 year-old adults in the Region. Afghanistan, Bahrain, Egypt, Jordan, Lebanon, Morocco, Pakistan and Tunisia had studies conducted within the past five years.
MENA Region has the highest regional prevalence of 16.2% and the second highest expected increase (86%) in the number of people with diabetes reaching 136 million by 2045. The MENA Region has the highest percentage (24.5%) of diabetes-related deaths in people of working age. Only 32.6 billion USD was spent on diabetes in MENA Region, representing 3.4% of the total spent worldwide, despite the region being home to 13.6% of people with diabetes worldwide.
| At a glance | 2000 | 2011 | 2021 | 2030 | 2045 |
|---|---|---|---|---|---|
| Diabetes estimates (20-79 y) | |||||
| People with diabetes, in 1,000s | 17,007.6 | 32,600.0 | 72,671.9 | 95,000.0 | 135,700.0 |
| Age-adjusted comparative prevalence of diabetes, % | 7.7 | 11.0 | 18.1 | 19.6 | 20.4 |
| People with undiagnosed diabetes, in 1,000s | - | - | 27,330.5 | - | - |
| Proportion of people with undiagnosed diabetes, % | - | - | 37.6 | - | - |
| Impaired glucose tolerance (IGT) estimates (20-79 y) | |||||
| People with IGT, in 1,000s | - | 23,900.0 | 47,610.8 | 59,000.0 | 80,500.0 |
| Age-adjusted comparative prevalence of IGT, % | - | 7.6 | 11.2 | 11.5 | 11.7 |
| Impaired fasting glucose (IFG) estimates (20-79 y) | |||||
| People with IFG, in 1,000s | - | - | 28,944.6 | 35,700.0 | 47,500.0 |
| Age-adjusted comparative prevalence of IFG, % | - | - | 6.1 | 6.2 | 6.3 |
| Mortality attributable to diabetes (20-79 y) | |||||
| Deaths attributable to diabetes | - | 276,400.0 | 796,362.0 | - | - |
| Proportion of diabetes-related deaths in people under 60 y, % | - | - | - | - | - |
| Type 1 diabetes estimates in children and adolescents | |||||
| New cases of type 1 diabetes (0-14 y), in 1,000s | 10.9 | 10.8 | 18.1 | - | - |
| New cases of type 1 diabetes (0-19 y), in 1,000s | - | - | 25.0 | - | - |
| Type 1 diabetes (0-14 y), in 1,000s | 45.3 | 64.9 | 108.9 | - | - |
| Type 1 diabetes (0-19 y), in 1,000s | - | - | 192.5 | - | - |
| Hyperglycaemia in pregnancy (HIP) (20-49 y) | |||||
| Live births affected by HIP | - | - | 2,354,069.4 | - | - |
| Prevalence of gestational diabetes mellitus (GDM), % | - | - | 14.1 | - | - |
| Live births affected by other types of diabetes first detected in pregnancy | - | - | 527,094.2 | - | - |
| Live births affected by other types of diabetes detected prior to pregnancy | - | - | 889,290.4 | - | - |
| Diabetes-related health expenditure | |||||
| Total diabetes-related health expenditure, USD million | - | 10,900.0 | 32,580.5 | 43,322.9 | 46,600.0 |
| Total diabetes-related health expenditure, ID million | 0.0 | - | 100,520.4 | 102,871.7 | 114,905.7 |
| Diabetes-related health expenditure per person, USD | - | 590.7 | 465.5 | 1,625.5 | 1,266.7 |
| Diabetes-related health expenditure per person, ID | - | - | 1,436.2 | 3,583.1 | 2,869.1 |
| Demographics | |||||
| Total adult population (20-79 y), in 1,000s | 219,800.0 | 356,000.0 | 448,205.9 | 539,659.1 | 703,000.0 |
| Population of children (0-14 y), in 1,000s | 197,311.0 | - | 249,588.1 | - | - |
| Population of children and adolescents (0-19 y), in 1,000s | - | - | 317,844.1 | - | - |